Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 6/20 | 0.42 |
| ▸ | CA9 | Q16790 | 2/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | FUCA1 | P04066 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 6/20 | 0.33 |
| ▸ | GBA1 | P04062 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28145005 | 1.00 | CA2 (0.42) | CA2CA9CA12FUCA1SMN1; SMN2 | |
| SCHEMBL209165 | 1.00 | CA2 (0.42) | CA2CA9CA12FUCA1SMN1; SMN2 | |
| SCHEMBL3712080 | 1.00 | CA2 (0.42) | CA2CA9CA12FUCA1SMN1; SMN2 | |
| SCHEMBL3712541 | 1.00 | CA2 (0.42) | CA2CA9CA12FUCA1SMN1; SMN2 | |
| SCHEMBL2504504 | 1.00 | CA2 (0.42) | CA2CA9CA12FUCA1SMN1; SMN2 | |
| SCHEMBL81581 | 1.00 | CA2 (0.42) | CA2CA9CA12FUCA1SMN1; SMN2 | |
| SCHEMBL23541364 | 0.78 | FUCA1 (0.48) | CA2CA9CA12FUCA1SMN1; SMN2 | |
| SCHEMBL12556709 | 0.78 | FUCA1 (0.48) | CA2CA9CA12FUCA1SMN1; SMN2 | |
| SCHEMBL11962132 | 0.78 | FUCA1 (0.48) | CA2CA9CA12FUCA1SMN1; SMN2 | |
| SCHEMBL22923476 | 0.78 | FUCA1 (0.48) | CA2CA9CA12FUCA1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010102673-A1 | HELLEBRIN AND HELLEBRIGENIN DERIVATIVES | UNIBIOSCREEN S.A. (BE) | 2010-09-16 | — | — | WO | claimed |
| WO-2009033505-A1 | HELLEBRIN DERIVATIVES | UNIBIOSCREEN S.A. (BE) | 2009-03-19 | — | — | WO | claimed |
| US-20060252708-A1 | Compositions of flavones and long chain fatty acid derivatives isolated from plants and methods related thereto for the control of prostate disorders | SHENZHEN CHIPSCREEN BIOSCIENCES, LTD. (GN) | 2006-11-09 | — | — | US | claimed |
| EP-0535595-B1 | Manufacture and use of novel glycosides of catechol estrogens | APPLIED BIOCHEMISTRY INST (JP) | 1997-07-02 | — | — | EP | claimed |
| US-5405944-A | Useful in the prevention and treatment of lipid peroxide- and free radical-related diseases | INSTITUTE OF APPLIED BIOCHEMISTRY (JP) | 1995-04-11 | — | — | US | claimed |
| EP-0535595-A2 | Manufacture and use of novel glycosides of catechol estrogens | Institute of Applied Biochemistry (JP) | 1993-04-07 | — | — | EP | claimed |
| WO-2024042239-A1 | GLYCOSYLATED PSILOCIN DERIVATIVES AND METHODS OF USE | CY BIOPHARMA AG (CH) | 2024-02-29 | — | — | WO | disclosed |
| US-11891360-B2 | Glycosylated psilocybin derivatives and methods of using | Enveric Biosciences Canada Inc. (CA) | 2024-02-06 | — | — | US | disclosed |
| WO-2023217800-A2 | GLYCOSYLATED COMPOSITIONS AND METHODS OF USE | CY BIOPHARMA AG (CH) | 2023-11-16 | — | — | WO | disclosed |
| WO-2023102659-A1 | GLYCOSYLATED ISOPROPYLAMINE MESCALINE DERIVATIVES AND METHODS OF USING | Enveric Biosciences Canada Inc. (CA) | 2023-06-15 | — | — | WO | disclosed |
| WO-2023102658-A1 | GLYCOSYLATED MESCALINE DERIVATIVES AND METHODS OF USING | Enveric Biosciences Canada Inc. (CA) | 2023-06-15 | — | — | WO | disclosed |
| US-20230086396-A1 | GLYCOSYLATED PSILOCYBIN DERIVATIVES AND METHODS OF USING | MAGICMED INDUSTRIES INC. (CA) | 2023-03-23 | — | — | US | disclosed |
| US-11564967-B1 | Oral compositions containing extracts of a betel leaf and related methods | Huynh, Tran Ky (VN) | 2023-01-31 | — | — | US | disclosed |
| US-5739302-A | SUBJECTING ACETOXYESTROGEN TO FRIES REARRANGEMENT IN PRESENCE OF ACETYL CHLORIDE, USING DAKIN REACTION TO REPLACE ACETYL GROUP WITH HYDROXYL GROUP AT ALKALINE PH | INSTITUTE OF APPLIED BIOCHEMISTRY (JP) | 1998-04-14 | — | — | US | disclosed |
| EP-0535595-B1 | Manufacture and use of novel glycosides of catechol estrogens | APPLIED BIOCHEMISTRY INST (JP) | 1997-07-02 | — | — | EP | disclosed |
| EP-0688785-A2 | Manufacture of catechol estrogens derivatives | Institute of Applied Biochemistry (JP) | 1995-12-27 | — | — | EP | disclosed |
| US-5405944-A | Useful in the prevention and treatment of lipid peroxide- and free radical-related diseases | INSTITUTE OF APPLIED BIOCHEMISTRY (JP) | 1995-04-11 | — | — | US | disclosed |
| US-5405944-A | Useful in the prevention and treatment of lipid peroxide- and free radical-related diseases | INSTITUTE OF APPLIED BIOCHEMISTRY (JP) | 1995-04-11 | — | — | US | disclosed |
| EP-0535595-A2 | Manufacture and use of novel glycosides of catechol estrogens | Institute of Applied Biochemistry (JP) | 1993-04-07 | — | — | EP | disclosed |
| EP-0535595-A2 | Manufacture and use of novel glycosides of catechol estrogens | Institute of Applied Biochemistry (JP) | 1993-04-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060252708-A1 | Compositions of flavones and long chain fatty acid derivatives isolated from plants and methods related thereto for the control of prostate disorders | FASN, RFT1, FFAR1 | CA2 3808/4885CA9 4039/4885CA12 4595/4885 |
| US-20230086396-A1 | GLYCOSYLATED PSILOCYBIN DERIVATIVES AND METHODS OF USING | UGT8, UGT2B7, UGT1A9 | CA2 4857/4885CA9 3774/4885CA12 3230/4885 |
| US-11891360-B2 | Glycosylated psilocybin derivatives and methods of using | UGT8, UGT2B7, UGT1A9 | CA2 4857/4885CA9 3774/4885CA12 3230/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.